Cargando…

Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe

OBJECTIVE: The main objective of the study was to investigate major differences among European countries in implementing infection prevention and control (IPC) measures and reasons for reduced compliance. DESIGN: An online survey including experts in IPC and a gap analysis were conducted to identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Tacconelli, Evelina, Buhl, Michael, Humphreys, Hilary, Malek, Veronika, Presterl, Elisabeth, Rodriguez-Baño, Jesús, Vos, Margreet C, Zingg, Walter, Mutters, Nico T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530321/
https://www.ncbi.nlm.nih.gov/pubmed/31110101
http://dx.doi.org/10.1136/bmjopen-2018-027683
_version_ 1783420615024181248
author Tacconelli, Evelina
Buhl, Michael
Humphreys, Hilary
Malek, Veronika
Presterl, Elisabeth
Rodriguez-Baño, Jesús
Vos, Margreet C
Zingg, Walter
Mutters, Nico T
author_facet Tacconelli, Evelina
Buhl, Michael
Humphreys, Hilary
Malek, Veronika
Presterl, Elisabeth
Rodriguez-Baño, Jesús
Vos, Margreet C
Zingg, Walter
Mutters, Nico T
author_sort Tacconelli, Evelina
collection PubMed
description OBJECTIVE: The main objective of the study was to investigate major differences among European countries in implementing infection prevention and control (IPC) measures and reasons for reduced compliance. DESIGN: An online survey including experts in IPC and a gap analysis were conducted to identify major limitations in implementing IPC guidelines. SETTING: Europe. MAIN OUTCOME MEASURES: Four areas were targeted: (1) healthcare structure, (2) finances, (3) culture and (4) education and awareness. Perceived compliance to IPC measures was classified as low (<50%), medium (50% to 80%) and high (>80%). Countries were classified in three regions: North-Western Europe (NWE), Eastern Europe (EE) and Southern Europe (SE). RESULTS: In total, 482 respondents from 34 out of 44 (77.3%) European countries participated. Respondents reported availability of national guidelines to control multidrug-resistant Gram-negatives (MDR-GN) in 20 countries (58.0%). According to participants, compliance with IPC measures ranged from 17.8% (screening at discharge) to 96.0% (contact precautions). Overall, three areas were identified as critical for the compliance rate: (1) number of infection control staff, (2) IPC dedicated educational programmes and (3) number of clinical staff. Analysis of reasons for low compliance showed high heterogeneity among countries: participants from NWE and SE deemed the lack of educational programmes as the most important, while those from EE considered structural reasons, such as insufficient single bed rooms or lacking materials for isolation, as main contributors to the low compliance. CONCLUSIONS: Although national guidelines to reduce the spread of MDR-GN are reported in the majority of the European countries, low compliance with IPC measures was commonly reported. Reasons for the low compliance are multifactorial and vary from region to region. Cross-country actions to reduce the spread of MDR-GN have to consider structural and cultural differences in countries. Locally calibrated interventions may be fruitful in the future.
format Online
Article
Text
id pubmed-6530321
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65303212019-06-07 Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe Tacconelli, Evelina Buhl, Michael Humphreys, Hilary Malek, Veronika Presterl, Elisabeth Rodriguez-Baño, Jesús Vos, Margreet C Zingg, Walter Mutters, Nico T BMJ Open Infectious Diseases OBJECTIVE: The main objective of the study was to investigate major differences among European countries in implementing infection prevention and control (IPC) measures and reasons for reduced compliance. DESIGN: An online survey including experts in IPC and a gap analysis were conducted to identify major limitations in implementing IPC guidelines. SETTING: Europe. MAIN OUTCOME MEASURES: Four areas were targeted: (1) healthcare structure, (2) finances, (3) culture and (4) education and awareness. Perceived compliance to IPC measures was classified as low (<50%), medium (50% to 80%) and high (>80%). Countries were classified in three regions: North-Western Europe (NWE), Eastern Europe (EE) and Southern Europe (SE). RESULTS: In total, 482 respondents from 34 out of 44 (77.3%) European countries participated. Respondents reported availability of national guidelines to control multidrug-resistant Gram-negatives (MDR-GN) in 20 countries (58.0%). According to participants, compliance with IPC measures ranged from 17.8% (screening at discharge) to 96.0% (contact precautions). Overall, three areas were identified as critical for the compliance rate: (1) number of infection control staff, (2) IPC dedicated educational programmes and (3) number of clinical staff. Analysis of reasons for low compliance showed high heterogeneity among countries: participants from NWE and SE deemed the lack of educational programmes as the most important, while those from EE considered structural reasons, such as insufficient single bed rooms or lacking materials for isolation, as main contributors to the low compliance. CONCLUSIONS: Although national guidelines to reduce the spread of MDR-GN are reported in the majority of the European countries, low compliance with IPC measures was commonly reported. Reasons for the low compliance are multifactorial and vary from region to region. Cross-country actions to reduce the spread of MDR-GN have to consider structural and cultural differences in countries. Locally calibrated interventions may be fruitful in the future. BMJ Publishing Group 2019-05-19 /pmc/articles/PMC6530321/ /pubmed/31110101 http://dx.doi.org/10.1136/bmjopen-2018-027683 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Infectious Diseases
Tacconelli, Evelina
Buhl, Michael
Humphreys, Hilary
Malek, Veronika
Presterl, Elisabeth
Rodriguez-Baño, Jesús
Vos, Margreet C
Zingg, Walter
Mutters, Nico T
Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe
title Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe
title_full Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe
title_fullStr Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe
title_full_unstemmed Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe
title_short Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe
title_sort analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in europe
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530321/
https://www.ncbi.nlm.nih.gov/pubmed/31110101
http://dx.doi.org/10.1136/bmjopen-2018-027683
work_keys_str_mv AT tacconellievelina analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope
AT buhlmichael analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope
AT humphreyshilary analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope
AT malekveronika analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope
AT presterlelisabeth analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope
AT rodriguezbanojesus analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope
AT vosmargreetc analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope
AT zinggwalter analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope
AT muttersnicot analysisofthechallengesinimplementingguidelinestopreventthespreadofmultidrugresistantgramnegativesineurope